...
首页> 外文期刊>Journal of neuro-oncology. >Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody.
【24h】

Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody.

机译:大剂量静脉内免疫球蛋白治疗后伴抗Purkinje细胞抗体的小肿瘤旁小脑变性患者的神经功能改善。

获取原文
获取原文并翻译 | 示例
           

摘要

Paraneoplastic cerebellar degeneration (PCD) is a rare syndrome associated with systemic malignancies, most in lung and ovarian cancer. Cerebellar ataxia has previously been associated with the presence of anti-Purkinje cell antibodies (anti-Yo) in the serum and cerebrospinal fluid and responses to therapy are uncommon. We reported two patients were identified with delayed onset of PCD associated with high titer of CSF anti-Yo (1:30,000, 1:320 U/ml) and a marked elevation of tumor markers for ovarian cancer (CA-125 17,700 ng/ml, 43 ng/ml) titer 1 year and 6 months prior to discovery of the carcinoma. Both developed subacute onset of severe ataxia, dysarthria, tremor, nystagmus with progression to severe debilitation (wheelchair bound or bedridden status). One of these patients also developed dysphagia that required PEG tube feeding. They were treated with six cycles of intravenous immunoglobulin (IVIG) 0.4 gm/kg/day x 5 days, every 4-6 weeks in conjunction with combination chemotherapy of Taxol and Carboplatin after the surgical resection of ovarian cancer. In each case, a significant improvement of neurological deficits were seen after the third cycle of IVIG, approximately 4 months after initiation of treatment. This type of delayed response is contrary to the previous reports. Both patients could ambulate without assistance in correlation with dramatic decrease in anti-Yo titer (1:80, 1:320 U/ml) and CA-125 (11 ng/ml, 8 ng/ml). This is a first report of benefit from IVIG in patients with late onset of PCD, which showed a delayed response with significant neurological improvement.
机译:副肿瘤性小脑变性(PCD)是一种与全身性恶性肿瘤相关的罕见综合征,多数发生在肺癌和卵巢癌中。以前,小脑性共济失调与血清和脑脊液中存在抗浦肯野细胞抗体(anti-Yo)有关,对治疗的反应并不常见。我们报道了两名患者,他们被确认患有PCD延迟发作,高滴度的CSF抗Yo(1:30,000,1:320 U / ml)和卵巢癌的肿瘤标志物明显升高(CA-125 17,700 ng / ml) ,发现癌症前1年和6个月,滴定度为43 ng / ml)。两者均发生严重共济失调,构音障碍,震颤,眼球震颤的亚急性发作,并发展为严重的衰弱(轮椅束缚或卧床状态)。这些患者之一也出现吞咽困难,需要吞咽PEG管。在卵巢癌手术切除后,每4-6周接受6个周期的静脉注射免疫球蛋白(IVIG)0.4 gm / kg /天x 5天,并结合紫杉醇和卡铂联合化疗。在每种情况下,在开始治疗约4个月的IVIG第三周期后,神经功能缺损都得到了明显改善。这种类型的延迟响应与以前的报告相反。两名患者都可以在没有帮助的情况下进行走动,与抗-Yo滴度(1:80,1:320 U / ml)和CA-125(11 ng / ml,8 ng / ml)的急剧下降相关。这是PCIG发作较晚的患者从IVIG获益的第一篇报道,该研究显示反应延迟,神经系统显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号